Skip to main content
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Subscribe
Home
Articles
Latest Issue
Issue Archive
Online First
Special Issues
Categories
Anemia Resources
HOPA Corner
Web Exclusives
All Web Exclusives
Cancer, Clearly
Emerging Data and Trends in HR-Positive/HER2-Negative Breast Cancer
Did You Know? Beyond the Data
Case-Based Exchanges
Conference Correspondent
ESMO 2025 - Wrap-Up: Triple-Negative Breast Cancer
ESMO 2025 - Early Breast Cancer
ASCO 2025 - Breast Cancer Faculty Commentary
ASCO 2025 - Wrap-Up: Triple-Negative Breast Cancer
Biosimilar Resources
Managing Adverse Events in Patients Utilizing Antibody-Drug Conjugate Therapy
Voices From ASCO 2025
Interview with the Innovators
Rapid Reactions
FDA Oncology Update
Videos
Press Releases
Quick Quiz
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor/Perspectives
Join Our Peer Review
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
Editorial Board
Editorial Process
Advertising Policy
Advertise
Cholangiocarcinoma
Drug Sensitivities Are Predicted with Tumor Organoid-Based Functional Analysis in Patients with Cholangiocarcinoma
Read More
Cholangiocarcinoma
Importance of PKN2 Signaling in the Development of Drug Resistance in Patients with CCA and FGFR2 Fusion
Read More
Cholangiocarcinoma
Correlation of Next-Generation Sequencing and PCR Analysis of ctDNA with Clinical Outcomes and Emerging Mutations Linked to Drug Resistance
Read More
Cholangiocarcinoma
Benefits of Lenvatinib plus Pembrolizumab in Solid Tumors, Including Biliary Tract Cancer
Read More
Cholangiocarcinoma
Reduction of Tumor Burden, Promotion of Hepatic Progenitor-Cell Differentiation, and Induction of Antitumor Immunity in Intrahepatic CCA with Ivosidenib, a Selective IDH1 Inhibitor
Read More
Cholangiocarcinoma
Neoadjuvant Chemoradiation and Orthotopic Liver Transplantation versus Definitive Chemoradiation in Unresectable CCA
Read More
Cholangiocarcinoma
NTRK Gene Fusions in Biliary Tract Cancers
Read More
Cholangiocarcinoma
CXCR2+ Granulocytic Myeloid-Derived Suppressor Cells with the Development of CCA: A Possible Target for Intervention
Read More
Cholangiocarcinoma
Phase 2 Study of Copanlisib plus Gemcitabine and Cisplatin in Advanced CCA
Read More
Cholangiocarcinoma
Hepatocyte-Derived Intrahepatic CCA Requires YAP and SOX9
Read More
118
119
120
121
122
123
124
Page 121 of 199
Results 1201 - 1210 of 1986
